1. HBW Insight
  2. >>Leadership

FDA Leadership Shuffle Continues: Lowell Zeta Returns As OPDP, OGD Leaders Depart

 
• By Sue Sutter and Derrick Gingery

Lowell Zeta, a senior counselor at the FDA from 2020 to 2021, returns as deputy commissioner for strategic initiatives. The agency also names a new acting CIO and acting CVM director, but OGD's Ted Sherwood and OPDP's Catherine Gray retired.

Man leaving
The FDA continues to lose longtime senior staffers as Commissioner Martin Makary builds his team. (Shutterstock)
Key Takeaways
  • Lowell Zeta, a senior counselor to the commissioner in 2020, has rejoined the agency as deputy commissioner for strategic initiatives, and is responsible for helping to implement cross-agency projects.
  • The agency also announced a new acting chief information officer and acting director of the Center for Veterinary Medicine.
  • CDER’s Office of Generic Drugs and Office of Prescription Drug Promotion lost senior officials to retirement.

Lowell Zeta, a former US Food and Drug Administration staffer well versed in biopharma regulatory, legal and compliance matters, is joining Commissioner Martin Makary’s

Makary announced Zeta’s appointment, along with the elevation of two agency veterans, in

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Leadership

People On The Move: Appointments At ANEPF, Inula, Opella

 
• By Tom Gallen

A round-up of the latest consumer health people moves: ANEFP elects president; Inula Group appoints CEO; Opella names ANZ head.

In Blistering Criticism, Health Subcommittee Democrat Warns Of Kennedy’s ‘Toxic Brew’ Plans

 
• By Malcolm Spicer

Trump’s first-term public health appointees “were serious people doing serious work in a bipartisan nature,” but HHS Secretary Robert F. Kennedy and other current presidential advisors “are not serious people,” says Massachusetts’ Jake Auchincloss.

MAHA Translates To ‘Change The Broken System’ At US FDA For Commissioner Makary

 
• By Malcolm Spicer

Among FDA's diversions from accepted practices is not going “through the bureaucracy” of advisory committees for experts’ input on potential changes to improve the safety and nutrition profile of food products, says Commissioner Martin Makary.

Commissioner Makary Outlines Expectations For US FDA: ‘Challenge Deeply Held Assumptions’

 
• By Malcolm Spicer

“It was a little hard to begin after the change or the reduction in force. We're doing everything we can to do an assessment, restore some services of individuals, and also try to rebuild the culture, because it is a great culture,” says FDA Commissioner Martin Makary during FDLI conference.

More from HBW Insight

US FDA Supplement Office Chief Eyes ‘Movement’ This Year On NDI Notifications Final Guidance

 
• By Malcolm Spicer

“We've made some progress and really hope to see some movement as we move forward this year,” says FDA Office of Dietary Supplement Programs director Cara Welch.

People On The Move: Appointments At ANEPF, Inula, Opella

 
• By Tom Gallen

A round-up of the latest consumer health people moves: ANEFP elects president; Inula Group appoints CEO; Opella names ANZ head.

Over The Counter: Taking Real-World Evidence Seriously, With IQVIA Consumer Health’s Volker Spitzer

 
• By David Ridley

In part 2 of HBW Insight's interview, IQVIA Consumer Health's vice president of global research and development and real-world evidence services, Volker Spitzer, explains how to approach real world evidence so that regulators recognize its validity, in supporting Rx-to-OTC switch applications, for example.